InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated:30 May 2023

PALEO: The purpose of this study is to investigate the effects of the addition of stereotactic body radiotherapy and immunotherapy (durvalumab) to a well tolerated 2-week chemotherapy and radiation treatment regimen in people with oesophageal cancer that has spread to another area of the bodyPhase II clinical trial of chemoradioimmunotherapy for the ALleviation of oEsOphageal cancer complications

Clinical summary


Eligible participants will receive 10 treatments of radiation therapy to the primary oesophageal cancer, with one treatment given on each working day for 2 weeks. In addition, all participants will receive chemotherapy (including carboplatin and paclitaxel) given intravenously once per week for the same 2 weeks as the radiation therapy. Durvalumab (immunotherapy) will be given intravenously every 4 weeks from the beginning of radiation therapy. After this, participants will continue to receive durvalumab intravenously once every 4 weeks for up to 24 months. If the participants have a metastatic tumour, they will also be given 3 doses of radiation therapy in one week. This radiation therapy will be received 4 weeks after the initial radiation therapy is completed. It is hoped that this trial can help determine if this chemotherapy with immunotherapy and radiation therapy combination is effective in increasing the ability of the body's immune system to prevent worsening of the cancer and improve swallowing.





Trial Acronym


More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Commercial Sponsor

Varian Medical Systems, Inc, Australasian Gastro-Intestinal Trials Group (AGITG)

Scientific Title

Phase II clinical trial of chemoradioimmunotherapy for the ALleviation of oEsOphageal cancer complications



  • You have certain types of non-cancer medical conditions.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.


  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support


Cancer Connect

Speak with someone who has cancer clinical trial experience.

Learn more


Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more


Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more